Sangamo Therapeutics Sells Key Assets in Chapter 11 Reorganization
Event summary
- Sangamo Therapeutics has entered into asset sale agreements with Lilly and Astellas as part of a voluntary Chapter 11 reorganization.
- Lilly will acquire Sangamo’s capsid delivery platform, zinc finger platform, MINT platform, and prion disease program ST-506.
- Astellas will acquire the Fabry disease program isaralgagene civaparvovec (ST-920).
- Sangamo has secured debtor-in-possession (DIP) financing from Northridge ATM to support ongoing operations.
The big picture
Sangamo Therapeutics’ Chapter 11 filing and asset sales to Lilly and Astellas reflect a strategic pivot to maximize value amid financial challenges. The move underscores the competitive interest in Sangamo’s genomic medicine platforms, particularly in addressing neurological diseases. The outcome of this restructuring will signal broader trends in biotech asset divestitures and partnerships with large pharmaceutical players.
What we're watching
- Strategic Asset Valuation
- How the court-supervised auction process will determine the final value of Sangamo’s remaining assets, including ST-503 and giroctocogene fitelparvovec.
- Operational Continuity
- Whether Sangamo can maintain normal operations during the Chapter 11 proceedings and secure sufficient liquidity through DIP financing.
- Industry Interest
- The level of interest from other bidders in acquiring Sangamo’s non-included assets, particularly its cell therapy and Treg platforms.
Related topics